Tonix Pharmaceuticals Holding Corp. Income Statement

Income Statement Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 7.77M10.09M
Cost of Revenue 4.74M7.76M
Gross Profit 3.03M2.33M
Operating items
Research & Development 13.34M17.56M18.19M36.16M68.84M81.88M86.66M39.97M
Selling, General & Administrative 7.95M8.76M10.64M14.35M23.47M30.21M34.75M40.10M
Other Operating Expenses -130.34M-119.91M66.72M
Operating Expenses 21.29M26.32M28.83M50.51M92.31M112.09M126.15M146.79M
Operating Income -21.29M-26.32M-28.83M-50.51M-92.31M-112.09M-118.38M-136.70M
EBIT -21.29M-26.32M-28.83M-50.51M-92.31M-112.09M-118.38M-136.70M
Non-operating items
Non Operating Investment Income 6.15M
Interest & Investment Income 0.17M0.23M0.21M0.05M0.03M1.87M1.72M
Other Non Operating Income 1.72M-2.08M
Non Operating Income 1.72M-2.08M
Net income details
EBT -20.49M-21.50M-22.63M-41.16M-73.69M-88.48M-98.20M-136.70M
Profit After Tax -21.12M-26.09M-28.62M-50.46M-92.29M-110.22M-116.66M-136.70M
Income from Continuing Operations -20.49M-21.50M-22.63M-41.16M-73.69M-88.48M-98.20M-136.70M
Consolidated Net Income -20.49M-21.50M-22.63M-41.16M-73.69M-88.48M-98.20M-136.70M
Income towards Parent Company -20.49M-21.50M-22.63M-41.16M-73.69M-88.48M-98.20M-136.70M
Preferred Dividend Payments 3.27M2.47M1.26M6.66M
Net Income towards Common Stockholders -21.12M-29.36M-31.09M-52.17M-92.29M-116.88M-116.66M-130.04M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.01M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.01M-0.00M
Shares Outstanding (Weighted Average) 0.00M0.00M0.00M0.00M0.01M1.87M
Shares Outstanding (Diluted Average) 0.01M0.74M
EBITDA -21.29M-26.32M-28.83M-50.51M-92.31M-112.09M-118.38M-136.70M